Literature DB >> 3009755

Effect of ketanserin on the in vitro regulation of aldosterone.

S Rocco, M Boscaro, D D'Agostino, D Armanini, G Opocher, F Mantero.   

Abstract

Serotonin (5-HT) is known to be a potent stimulator of aldosterone release in vitro and, to a lesser degree, in vivo. Since ketanserin, a specific 5-HT2-receptor antagonist, decreases aldosterone levels in some hypertensive patients, we have performed in vitro experiments to elucidate the mechanism by which ketanserin interferes with aldosterone regulation. After collagenase dispersion, rat zona glomerulosa cells were either perfused and resuspended in Biogel or incubated in Earle's medium and bovine serum albumin. The cells were stimulated with serotonin, angiotensin II, potassium (K+) and adrenocorticotrophic hormone (ACTH) in the presence or absence of ketanserin. Ketanserin did not decrease baseline aldosterone secretion although it reduced the stimulatory capacity of serotonin and K+, and had a minimal effect on ACTH. Furthermore, we demonstrated that ketanserin is able to have a significant effect on the adrenal response to angiotensin II. These data indicate that antiserotoninergic agents may act directly at the level of the adrenal glomerulosa by interfering with specific serotoninergic receptors and modifying the adrenal sensitivity to angiotensin II and K+. The importance of these findings in the clinical use of these antihypertensive drugs remains to be established.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3009755

Source DB:  PubMed          Journal:  J Hypertens Suppl        ISSN: 0952-1178


  2 in total

1.  Acute and chronic ketanserin in essential hypertension: antihypertensive mechanisms and pharmacokinetics.

Authors:  R Donnelly; H L Elliott; P A Meredith; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1987-11       Impact factor: 4.335

2.  Effects of pretreatment with dexfenfluramine and fluoxetine on metoclopramide-induced aldosterone secretion in healthy volunteers.

Authors:  de K Sommers; J R Snyman; M van Wyk
Journal:  Clin Drug Investig       Date:  1998       Impact factor: 2.859

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.